RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia

Leukemias are routinely sub-typed for risk/outcome prediction and therapy choice using acquired mutations and chromosomal rearrangements. Down syndrome acute lymphoblastic leukemia (DS‐ALL) is characterized by high frequency of CRLF2‐rearrangements, JAK2‐mutations, or RAS‐pathway mutations. Intrigui...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncogene
Glavni autori: Koschut, David, Ray, Debleena, Li, Zhenhua, Giarin, Emanuela, Groet, Jürgen, Alić, Ivan, Kham, Shirley Kow-Yin, Chng, Wee Joo, Ariffin, Hany, Weinstock, David M., Yeoh, Allen Eng-Juh, Basso, Giuseppe, Nižetić, Dean
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7843419/
https://ncbi.nlm.nih.gov/pubmed/33247204
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-020-01567-7
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items